ES2715556T3 - Terapia combinada con roneparstat del mieloma múltiple - Google Patents
Terapia combinada con roneparstat del mieloma múltiple Download PDFInfo
- Publication number
- ES2715556T3 ES2715556T3 ES16709148T ES16709148T ES2715556T3 ES 2715556 T3 ES2715556 T3 ES 2715556T3 ES 16709148 T ES16709148 T ES 16709148T ES 16709148 T ES16709148 T ES 16709148T ES 2715556 T3 ES2715556 T3 ES 2715556T3
- Authority
- ES
- Spain
- Prior art keywords
- roneparstat
- melphalan
- use according
- multiple myeloma
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCCC(CC)(*C)O[C@@](C)(CC1)C(C)**[C@@]1C=CCNC Chemical compound CCCCC(CC)(*C)O[C@@](C)(CC1)C(C)**[C@@]1C=CCNC 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562129221P | 2015-03-06 | 2015-03-06 | |
| US201562153899P | 2015-04-28 | 2015-04-28 | |
| PCT/IB2016/051196 WO2016142814A1 (en) | 2015-03-06 | 2016-03-03 | Roneparstat combined therapy of multiple myeloma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2715556T3 true ES2715556T3 (es) | 2019-06-04 |
Family
ID=55521766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16709148T Active ES2715556T3 (es) | 2015-03-06 | 2016-03-03 | Terapia combinada con roneparstat del mieloma múltiple |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10576101B2 (enExample) |
| EP (2) | EP3453389A1 (enExample) |
| JP (1) | JP2018512394A (enExample) |
| KR (1) | KR20170138405A (enExample) |
| CN (1) | CN107645954A (enExample) |
| AU (1) | AU2016230859A1 (enExample) |
| BR (1) | BR112017018869A2 (enExample) |
| CA (1) | CA2978040A1 (enExample) |
| DK (1) | DK3265075T3 (enExample) |
| ES (1) | ES2715556T3 (enExample) |
| HK (1) | HK1245107A1 (enExample) |
| HU (1) | HUE042681T2 (enExample) |
| MX (1) | MX2017011093A (enExample) |
| PL (1) | PL3265075T3 (enExample) |
| PT (1) | PT3265075T (enExample) |
| WO (1) | WO2016142814A1 (enExample) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8727157D0 (en) * | 1987-11-19 | 1987-12-23 | Wellcome Found | Pharmaceutical formulations |
| IT1316986B1 (it) | 2000-01-25 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica. |
| US20050137167A1 (en) | 2001-09-12 | 2005-06-23 | Benito Casu | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| US7781416B2 (en) | 2000-01-25 | 2010-08-24 | Sigma-Tau Research Switzerland S.A. | Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| WO2009151569A2 (en) * | 2008-06-09 | 2009-12-17 | Combinatorx, Incorporated | Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders |
-
2016
- 2016-03-03 US US15/556,183 patent/US10576101B2/en not_active Expired - Fee Related
- 2016-03-03 ES ES16709148T patent/ES2715556T3/es active Active
- 2016-03-03 EP EP18202120.4A patent/EP3453389A1/en not_active Withdrawn
- 2016-03-03 MX MX2017011093A patent/MX2017011093A/es unknown
- 2016-03-03 DK DK16709148.7T patent/DK3265075T3/en active
- 2016-03-03 WO PCT/IB2016/051196 patent/WO2016142814A1/en not_active Ceased
- 2016-03-03 CN CN201680012508.0A patent/CN107645954A/zh active Pending
- 2016-03-03 CA CA2978040A patent/CA2978040A1/en not_active Abandoned
- 2016-03-03 HU HUE16709148A patent/HUE042681T2/hu unknown
- 2016-03-03 JP JP2017546847A patent/JP2018512394A/ja active Pending
- 2016-03-03 BR BR112017018869A patent/BR112017018869A2/pt not_active IP Right Cessation
- 2016-03-03 AU AU2016230859A patent/AU2016230859A1/en not_active Abandoned
- 2016-03-03 PL PL16709148T patent/PL3265075T3/pl unknown
- 2016-03-03 HK HK18104587.1A patent/HK1245107A1/zh unknown
- 2016-03-03 EP EP16709148.7A patent/EP3265075B1/en active Active
- 2016-03-03 PT PT16709148T patent/PT3265075T/pt unknown
- 2016-03-03 KR KR1020177026179A patent/KR20170138405A/ko not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| PT3265075T (pt) | 2019-03-25 |
| EP3265075A1 (en) | 2018-01-10 |
| WO2016142814A1 (en) | 2016-09-15 |
| BR112017018869A2 (pt) | 2018-04-17 |
| US10576101B2 (en) | 2020-03-03 |
| EP3453389A1 (en) | 2019-03-13 |
| AU2016230859A1 (en) | 2017-08-17 |
| MX2017011093A (es) | 2018-02-19 |
| PL3265075T3 (pl) | 2020-10-05 |
| CN107645954A (zh) | 2018-01-30 |
| CA2978040A1 (en) | 2016-09-15 |
| HUE042681T2 (hu) | 2019-07-29 |
| DK3265075T3 (en) | 2019-04-08 |
| KR20170138405A (ko) | 2017-12-15 |
| US20180050061A1 (en) | 2018-02-22 |
| HK1245107A1 (zh) | 2018-08-24 |
| EP3265075B1 (en) | 2018-12-12 |
| JP2018512394A (ja) | 2018-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022017295A (ja) | Ｈｄａｃ阻害剤とｐｄ－ｌ１阻害剤との組み合わせ療法 | |
| ES3015717T3 (en) | A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis | |
| ES2589302T3 (es) | Métodos de tratamiento de mieloma múltiple utilizando terapias de combinación basadas en HuLuc63 con bortezemib | |
| ES3036485T3 (en) | Combination comprising everolimus and amcenestrant | |
| ES2815564T3 (es) | C. novyi para el tratamiento de tumores sólidos en seres humanos | |
| ES2969532T3 (es) | 3-(4-((4-(Morfolinometil-bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona para el tratamiento de lupus eritematoso sistémico | |
| CN112867512A (zh) | 联合疗法 | |
| JP2014500278A (ja) | 二重特異性ｓｃＦｖコンジュゲートの投薬量および投与 | |
| AU2021421391A1 (en) | Inhibitors of atp synthase - cosmetic and therapeutic uses | |
| ES2914781T3 (es) | Composiciones para el tratamiento de la amiloidosis | |
| ES2685974T3 (es) | Derivados de cefalosporina para tratar el cáncer | |
| BR112019009799A2 (pt) | método para tratar câncer em um paciente | |
| CN105813637A (zh) | 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂 | |
| ES2880444T3 (es) | Combinación de metotrexato y simvastatina para su uso en el tratamiento del osteosarcoma | |
| JP4672257B2 (ja) | エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 | |
| ES2826386T3 (es) | Antagonistas del receptor 5HT6 para uso en el tratamiento de la enfermedad de Alzheimer con apatía como comorbilidad | |
| ES2777501T3 (es) | Terapia de anticuerpos ANTI-VEGFR2 para carcinoma hepatocelular | |
| WO2021133862A1 (en) | Targeting the intrinsic apoptotic machinery in glioblastoma | |
| US20240197904A1 (en) | Combination therapy for treating glioblastoma | |
| JP7504106B2 (ja) | がんの処置のための組合せ物 | |
| TW201306833A (zh) | 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合 | |
| DK3265075T3 (en) | COMBINATION TREATMENT OF MULTIPLE MYELOMA WITH RONEPARSTAT | |
| ES2688464T3 (es) | Combinación de un inhibidor de la quinasa PI3 con paclitaxel para su uso en el tratamiento o la prevención de un cáncer de cabeza y cuello | |
| WO2022016231A1 (en) | Methods of treatment | |
| WO2025117739A1 (en) | Compositions and methods for treating cancer |